



# HHS Public Access

Author manuscript

*J Hum Genet.* Author manuscript; available in PMC 2018 July 10.

Published in final edited form as:

*J Hum Genet.* 2018 March ; 63(3): 327–337. doi:10.1038/s10038-017-0384-9.

## Genome-wide association study of homocysteine in African Americans from the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Coronary Artery Risk in Young Adults study

**Laura M. Raffield\***,

Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599

**Jaclyn Ellis\***,

Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599

**Nels C. Olson,**

Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405

**Qing Duan,**

Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599

**Jin Li,**

Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599

**Peter Durda,**

Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405

**Nathan Pankratz,**

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America, 55455

**Brendan J. Keating,**

Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America, 19104

**Christina L. Wassel,**

Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405

**Mary Cushman,**

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Address correspondence and reprint requests to: Laura M. Raffield, Department of Genetics, University of North Carolina, 5100 Genetic Medicine Building, 120 Mason Farm Road, Chapel Hill, NC, 27599, United States. [laura\\_raffield@unc.edu](mailto:laura_raffield@unc.edu), Phone: (919) 966-7255. Fax: (919) 843-4682.

\*Contributed equally to this work

### Conflict of Interest

The authors do not have any conflicts of interest to declare.

Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405; Department of Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405

**James G. Wilson,**

Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, United States of America, 39216

**Myron D. Gross,**

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America, 55455

**Russell P. Tracy,**

Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405; Department of Biochemistry, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, United States of America, 05405

**Stephen S. Rich,**

Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States of America, 22908

**Alex P. Reiner,**

Department of Epidemiology, University of Washington, Seattle, WA, United States of America, 98195

**Yun Li,**

Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599; Department of Biostatistics, University of North Carolina, Chapel Hill, NC, United States of America, 27599

**Monte S. Willis,**

Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, 27599

**Ethan M. Lange, and**

Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, 80045

**Leslie A. Lange**

Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, 80045

## **Abstract**

Homocysteine (Hcy) is a heritable biomarker for CVD, peripheral artery disease, stroke, and dementia. Little is known about genetic associations with Hcy in individuals of African ancestry. We performed a genome-wide association study for Hcy in 4,927 AAs from the Jackson Heart Study (JHS), the Multi-Ethnic Study of Atherosclerosis (MESA), and the Coronary Artery Risk in Young Adults (CARDIA) study. Analyses were stratified by sex and results were meta-analyzed within and across sex. In the sex-combined meta-analysis, we observed genome-wide significant

evidence ( $p < 5.0 \times 10^{-8}$ ) for the *NOX4* locus (lead variant rs2289125,  $\beta = -0.15$ ,  $p = 5.3 \times 10^{-11}$ ). While the *NOX4* locus was previously reported as associated with Hcy in European American populations, rs2289125 remained genome-wide significant when conditioned on the previously reported lead variants. Previously reported genome-wide significant associations at *NOX4*, *MTR*, *CBS*, and *MMACHC* were also nominally ( $p < 0.050$ ) replicated in AAs. Associations at the *CPS1* locus, previously reported in females only, also was replicated specifically in females in this analysis, supporting sex-specific effects for this locus. These results suggest that there may be a combination of cross-population and population-specific genetic effects, as well as differences in genetic effects between males and females, in the regulation of Hcy levels.

## Introduction

Cardiovascular disease (CVD) is the leading cause of death in the US, accounting for approximately a third of deaths. African Americans (AAs) have elevated rates of CVD and CVD mortality; approximately 47% of AAs over 19 years of age have CVD<sup>1</sup>. Plasma homocysteine (Hcy) is an established marker for CVD, and elevated Hcy concentrations are associated with risk of venous thrombosis, coronary heart disease, stroke, peripheral artery disease, and atherosclerosis<sup>2-5</sup>. Due to the influence of multiple environmental factors, the role of Hcy in CVD is complex and remains incompletely understood. Age, sex, renal function, vitamin intake, cigarette smoking, and menopause are among the main environmental determinants of Hcy levels<sup>6</sup>. Elevated Hcy has also been associated with increased risk of dementia and Alzheimer's disease<sup>7</sup>. Hcy has an important genetic component, as heritability is estimated as 47%–70%, depending on the population<sup>8-11</sup>, and genetic mutations in enzymes for Hcy metabolism have long been known to be associated with Hcy level.

Hcy is synthesized by the demethylation of methionine. There are at least two functional variants (677C>T and 1298A>C) in the gene for methylenetetrahydrofolate reductase (*MTHFR*), which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate used for the remethylation of Hcy to methionine<sup>12</sup>. Homozygous functional variants in cystathionine- $\beta$ -synthase (*CBS*), which catalyzes the transsulfuration reaction converting Hcy to cystathionine, are known to markedly increase Hcy level and may increase risk of stroke and venous thrombosis<sup>13</sup>. Folic acid and vitamins B-6 and B-12 are involved in Hcy metabolism, and supplementation with these factors can lower Hcy concentrations<sup>14</sup>.

Genome-wide association studies (GWAS) have been conducted for Hcy in populations of European ancestry<sup>15-19</sup> and Filipinos<sup>20</sup>. All of these GWAS observed evidence for association with Hcy for common variants in the *MTHFR* locus. The largest GWAS meta-analysis yet conducted for Hcy included 44,147 subjects of European ancestry and discovered 13 loci associated with Hcy, with a risk score of these variants explaining around 5% of variation in Hcy levels. While this study by van Meurs et al. did not examine differential associations by sex<sup>19</sup>, some studies have observed sex-specific genetic effects on Hcy; a GWAS of 13,974 EA females from the Women's Genome Health Study (WGHS) identified and replicated the carbamoyl-phosphate synthase 1 (*CPS1*) locus, with *CPS1*

replicated only in females in the confirmatory sample<sup>15</sup>. The *CPS1* locus was also associated with Hcy in a GWAS of 1,786 Filipino women; additional analysis in the adult offspring of the original sample confirmed that the association is only observed in females<sup>20</sup>. Evidence for modification of genotype effects by sex has also been seen for *MTHFR* in the Filipino population; the effect magnitude of the 677C>T polymorphism was stronger in males than females<sup>20</sup>. Some studies have also found sex-specific associations of Hcy with clinical endpoints like peripheral artery disease<sup>4</sup>. Associations of Hcy-related polymorphisms with CVD events have also been assessed; evidence for association with coronary artery disease (CAD) is mixed<sup>19, 21</sup>, casting doubt on Hcy's causal role in CAD, but some recent studies have found Hcy-related polymorphisms were associated with stroke risk<sup>22, 23</sup> and peripheral artery disease<sup>24</sup>. Results from interventional trials of folic acid supplementation have found more promising results for stroke than CAD as well<sup>25</sup>. Some studies have also found associations of Hcy associated polymorphisms with Alzheimer's disease case/control status<sup>26, 27</sup>.

Less is known about the genetic determinants of Hcy levels in AAs. While fewer GWAS studies have been conducted in AAs for many quantitative traits, populations of African-ancestry are particularly well suited to both discovery of novel loci and fine-mapping of loci discovered in European populations, due to generally smaller regions of linkage disequilibrium and differing allele frequencies<sup>28</sup>. Exclusively European ancestry GWAS results can also not be assumed to transfer to other populations with uniform effects<sup>29</sup>. A recent small GWAS (n= 1,858) in AAs and Yoruba Nigerians confirmed the association of variants in *CBS* with Hcy in a candidate gene analysis and identified a novel genome-wide association with rs6940729, an intronic variant in the gene for CD2-associated protein (*CD2AP*)<sup>30</sup>. Candidate gene analyses have also been performed. The Coronary Artery Risk Development in Young Adults (CARDIA) study performed a candidate gene analysis of variants in *MTHFR*, *CBS* and two additional genes for Hcy enzymes before and after folic acid fortification, which was mandated by the US Food and Drug Administration in 1996. Significant associations were detected in both European Americans (EAs) and AAs in the pre-folic acid fortification era when jointly considering all tested loci; post-folic acid fortification, the independent association of the *MTHFR* 677C>T variant with Hcy was attenuated to non-significance in AAs<sup>31</sup>. In an analysis of 476 AA women from the WGHS, no association between the *MTHFR* 677C>T variant and Hcy was observed<sup>32</sup>.

To better elucidate the genetic determinants of Hcy levels in AAs, we assessed the heritability of Hcy levels in related individuals from the Jackson Heart Study (JHS) cohort and performed a GWAS meta-analysis of AA participants from three cohorts: JHS, the Multi-Ethnic Study of Atherosclerosis (MESA), and CARDIA. We also evaluated previously reported variants associated with Hcy to assess replication in this AA population.

## Materials and Methods

### Study populations and Hcy measurements

**JHS**—JHS is a longitudinal population-based study designed to assess the causes of the high prevalence of CVD among AAs in the Jackson, Mississippi metropolitan area. During the baseline examination period (2000–2004), 5,301 self-identified AAs were recruited

through random sampling from a commercial listing, participation in the Atherosclerosis Risk in Communities (ARIC) study, a structured volunteer sample designed to mirror the eligible population, and a nested family cohort. Participants were between 35 and 84 years old with the exception of the family cohort, where those  $\geq 21$  years old were eligible<sup>33</sup>. Fasting blood samples from the baseline visit were assayed for Hcy. Hcy was measured at the University of Minnesota, in conjunction with the University of Minnesota Medical Center, Fairview. Plasma Hcy was assayed by the fluorescence polarization immunoassay method, supplied by Abbott Diagnostics (Abbott Park, IL). A total of 2,961 JHS participants with genotype and phenotype data were included in this study.

**MESA**—MESA is a longitudinal population-based study of the prevalence, determinants, and progression of subclinical CVD. MESA includes 6,814 men and women aged 45–84 without prevalent CVD at baseline (2002–2002); the cohort is approximately 38% EA, 28% AA, 22% Hispanic American, and 12% Asian American (primarily Chinese). Participants were recruited from six field centers (Winston-Salem, NC, St. Paul, MN, Chicago, IL, Los Angeles, CA, New York, NY, and Baltimore, MD)<sup>34,35</sup>. Blood samples collected at baseline were processed with the use of a standardized protocol and stored at  $-80^{\circ}\text{C}$  until analyzed. Participants were asked to fast for 12 hours, avoid smoking on the morning of the exam, and avoid heavy exercise 12 hours before the exam. Total plasma Hcy was measured using high-performance liquid chromatography with fluorometric detection. A total of 1,628 AA MESA participants with genotype and phenotype data were included in this study.

**CARDIA**—CARDIA is a longitudinal study of cardiovascular disease risk initiated in 1985–86 in 5,115 AA and EA men and women, then aged 18–30 years. The CARDIA sample was recruited at four sites: Birmingham, AL, Chicago, IL, Minneapolis, MN, and Oakland, CA<sup>36,37</sup>. Six repeat examinations were performed; fasting serum samples that were collected in 2000 (year 15 visit, 74% retention) and stored at  $-70^{\circ}\text{C}$  were used for Hcy measurement. Hcy was measured in serum by a fluorescence polarization immunoassay (IMx Homocysteine Assay, Axis Biochemicals ASA, Oslo, Norway) using the IMx Analyzer (Abbott Diagnostics, Abbott Park, IL). A total of 338 AA CARDIA participants with genotype and phenotype data were included in this study.

### Genotyping and imputation

Genome-wide genotyping on all cohorts was performed using the Affymetrix 6.0 SNP Array (Affymetrix, Santa Clara, Calif). SNPs were excluded if they were genotyped successfully in less than 90% of samples; subjects were removed if less than 95% of SNPs were genotyped successfully. No SNPs were removed due to deviation from Hardy-Weinberg equilibrium (HWE) expectations because the AA population is an admixed population, which may result in departures from HWE expectations even under ideal conditions. After quality control, genotype data was available on ~800,000 autosomal SNPs. Imputation to the 1000 Genomes project reference panel (Phase I, Version 3, March 2012 release) was performed using MACH 1.0 and minimac<sup>38</sup>. Imputed variants with a minor allele frequency  $< 1\%$  or an imputation quality  $< 0.3$  were excluded from all analyses. Data was available across cohorts for ~16.8 million SNPs on autosomes and chromosome X in 4,927 AA subjects with Hcy

measures. All participants gave written informed consent prior to their inclusion in the studies, and all studies were overseen by the relevant Institutional Review Boards.

### Data analysis

Hcy levels were highly skewed and simple transformations (e.g. using natural logarithm) did not remedy numerous outliers. Hence, we used inverse normalized residuals, obtained from modeling Hcy on established non-genetic risk factors: age, BMI, and current smoking status. These residuals were used as our outcome measure to meet linear model assumptions of normally distributed residuals and to minimize influence of extreme values when modeling Hcy on genotype. Residuals were calculated separately by cohort and by sex. For heritability analyses, residuals were calculated for JHS participants in males and females together, adjusting for sex, to maximize sample size and avoid dividing families. Heritability estimation was performed using SOLAR 6.6.2 [6] using variance components-based methods. We assessed associations between Hcy (using normalized residuals) and individual SNPs under the additive model, with covariate adjustment for the first 10 principal components calculated using the program EIGENSTRAT<sup>39</sup> to control for potential population substructure. The association analyses were performed separately by cohort and by sex. Association analyses were performed using linear models implemented in MACH2QTL v.1.13 for MESA and CARDIA<sup>38</sup>; a mixed model approach (EMMAX<sup>40</sup>) with adjustment for a kinship matrix implemented in Efficient and Parallelizable Association Container Toolbox (EPACTS) 3.2.6 was used for JHS due to the inclusion of related individuals in both males-only and females-only analyses.

After obtaining cohort specific results, we performed fixed-effect, inverse variance-weighted meta-analyses across cohorts using the METAL software<sup>41</sup>, first separately by sex and then combining samples from both males and females. We used a conventional GWAS significance threshold ( $p=5.0 \times 10^{-8}$ ) to maintain an overall experimental type I error rate of ~5%. Finally, conditional analyses, where association analyses are repeated with additional covariate adjustment for the top SNP in the region, were performed for the *NOX4* region in order to assess evidence for multiple independent signals.

Replication of variants identified in previous GWAS was also attempted. Only the lead variant at each locus was included for each study. We did not have good quality imputation data for the *FGF21* intronic variant rs838133 ( $r^2 < 0.3$  in all cohorts), previously reported as the *FUT2* locus<sup>19</sup>, so this variant is not included in Table 3. While not genome-wide significant, we also included rs28635199 ( $\beta = -0.030$ ,  $p = 5.7 \times 10^{-6}$ ), the top variant at the *CBS* locus in a previous GWAS in individuals of African descent<sup>30</sup>. One published GWAS identified no genome-wide significant loci and thus was not included here<sup>18</sup>. If there were different lead variants in different studies at the same locus, both were included; several of the variants listed are in modest LD ( $r^2 > 0.2$  in 1000 Genomes Project data) in Europeans, the population in which the majority of variants were reported (rs9369898 and rs4267943 at *MUT*, rs154657 and rs1126464 at *DPEPI*, and rs6586282 with both rs28635199 and rs234709 at *CBS*). However, only the two reported *NOX4* variants (rs7130284 and rs11018628) are in high LD in Europeans ( $r^2 > 0.7$ ), though they are not in significant LD in

African populations ( $r^2 < 0.2$ ). Only the *MUT* variants and two of the *CBS* variants (rs6586282 and rs28635199) are also in modest LD ( $r^2 > 0.2$ ) in African populations.

## Results

Demographic characteristics of the 4,927 AA study participants are presented in Table 1. Consistent with prior reports, Hcy levels were higher in males. A higher proportion of males currently smoked while females had, on average, higher body mass index (BMI). The average age of participants was near 40 in CARDIA, near 50 in JHS, and near 60 in MESA. We assessed the heritability of Hcy in related males and females from JHS, which included a nested family study component. Inverse normalized residuals adjusted for age, sex, BMI, and current smoking status were analyzed in 1,355 related individuals. Heritability was estimated as 28% (standard error 7.2%,  $p = 1.7 \times 10^{-5}$ ) for Hcy; this significant heritability indicates that common genetic variants may contribute to variation in Hcy levels in AAs, which we assessed through a GWAS.

Three meta-analyses (combined-sex, males-only, and females-only) of genome-wide association results for inverse normalized Hcy levels were conducted. Lead variants are displayed in Table 2, and association statistics for these variants for each individual cohort are presented in Supplementary Table 1. Considering males and females separately, no significant heterogeneity between cohorts was observed for any of the lead variants ( $I^2$  18%,  $p = 0.30$ ). All nominally significant variants from each meta-analysis ( $p < 1.0 \times 10^{-6}$ ) are displayed in Supplementary Table 2. Manhattan plots and quantile-quantile plots for each meta-analysis are displayed in Supplementary Figures 1 and 2. In our combined-sex meta-analysis, genome-wide significant evidence ( $p < 5.0 \times 10^{-8}$ ) for association with Hcy was observed for chromosome 11 SNPs at the NADPH oxidase 4 (*NOX4*) locus (Supplementary Figure 3a). The lead variant at this locus was rs2289125 ( $\beta = -0.15$ ,  $p = 5.3 \times 10^{-11}$ ), which is either an intronic or a 5' UTR variant depending on the *NOX4* isoform. This variant is not in strong linkage disequilibrium (LD) ( $r^2 < 0.2$  in European and African populations) with a *NOX4* variant (rs7130284) previously reported to be associated with Hcy in an EA meta-analysis of males and females<sup>19</sup> or in LD with another variant (rs11018628) reported in a genome-wide analysis of EA females from the WGHS<sup>15</sup>. These two previously reported lead *NOX4* variants are in strong LD ( $r^2 = 0.7$ ,  $D' = 0.9$ ) in Europeans from the 1000 Genomes project but are not in strong LD in African participants ( $r^2 < 0.2$ ). As noted in Table 3, rs7130284 does not show compelling evidence for association with Hcy in the AA participants included in our meta-analysis ( $\beta = -0.069$ ,  $p = 0.023$ ) but the rs11018628 variant reported in WGHS approached borderline significance ( $\beta = -0.14$ ,  $p = 2.0 \times 10^{-6}$ ). Conditioning on rs7130284 only modestly attenuated the associations of rs2289125 ( $\beta = -0.15$ ,  $p = 2.8 \times 10^{-10}$ ) and rs11018628 ( $\beta = 0.12$ ,  $p = 1.1 \times 10^{-4}$ ) with Hcy. Similarly, when conditioned on rs11018628, rs2289125 was still genome-wide significant ( $\beta = -0.14$ ,  $p = 1.1 \times 10^{-9}$ ), and the association of rs7130284 with Hcy was non-significant ( $\beta = 0.0017$ ,  $p = 0.96$ ).

Conditioning on rs2289125 reduced the remaining signal at *NOX4* below genome-wide significance (Supplementary Figure 3b), though some residual signals remained. The lead variant at *NOX4* after conditioning on rs2289125 was rs145661799 ( $\beta = -0.34$ ,  $p = 3.1 \times$

$10^{-6}$ ); after conditioning on both rs2289125 and rs145661799, the lead variant was rs10765210 ( $\beta = 0.14$ ,  $p = 5.4 \times 10^{-7}$ ). Variant rs10765210 was less significant when conditioned on rs2289125 alone ( $\beta = 0.11$ ,  $p = 8.4 \times 10^{-5}$ ) and in the original analysis ( $\beta = 0.13$ ,  $p = 2.3 \times 10^{-6}$ ). These results may indicate the presence of multiple distinct signals at the locus.

In males-only analyses, we observed no genome-wide significant associations. A near genome-wide significant signal was observed for intergenic variant rs144009661 on chromosome 8 ( $\beta = 0.65$ ,  $p = 6.3 \times 10^{-8}$ , Supplementary Figure 4); the nearest gene is leucine zipper, putative tumor suppressor 1 (*LZTS1*). No significant evidence for association was observed at this locus in females ( $\beta = 0.052$ ,  $p = 0.59$ ). In females-only analyses, there were also no genome-wide significant variants. The lead variant was rs116810794 ( $\beta = -0.28$ ,  $p = 5.9 \times 10^{-7}$ , Supplementary Figure 5a), near *NOX4*. Adjustment for the lead *NOX4* variant in sex-combined analyses, rs2289125, attenuated this association in females ( $\beta = -0.22$ ,  $p = 1.5 \times 10^{-4}$ , Supplementary Figure 5b); we would also note that rs2289125 has better imputation quality across cohorts (0.82–0.87) than rs116810794 (0.67–0.70), increasing our confidence in the rs2289125 association.

### Comparison with other previously identified GWAS loci

Association statistics for 20 previously identified genome-wide significant variants for Hcy from six published studies<sup>15–17, 19, 20, 30</sup> are listed in Table 3; meta-analysis results from combined males and females, males-only, and females-only are displayed. As the Hcy phenotype transformations differed between studies,  $\beta$  values cannot be directly compared. However, out of 20 previously reported variants, 18 in our meta-analysis had the same direction of effect compared to previous studies of both males and females; 16 had the same direction of effect in the males-only analyses and 15 in females-only analyses (Table 3). Of these variants, 8 were at least nominally ( $p < 0.050$ ) associated in the meta-analysis of both males and females, with 4 of these same variants nominally associated in the males-only meta-analysis and 7 associated in the females-only meta-analysis. Along with the two *NOX4* polymorphisms previously discussed, all 3 previously reported lead variants at the *CBS* locus (rs28635199, rs6586282, and rs234709)<sup>15, 19, 30</sup> were associated ( $p = 6.5 \times 10^{-3}$ ) with Hcy in the sex-combined meta-analysis. 5-methyltetrahydrofolate-homocysteine methyltransferase (*MTR*) variant rs2275565 was also associated with Hcy levels in males and females ( $p = 2.7 \times 10^{-3}$ ).

In addition to the variants which replicated in the meta-analysis of both males and females, we observed sex-specific associations for some of these variants. There was an association between *CPS1* missense variant rs7422339 (now renamed rs1047891) and Hcy in females ( $p = 0.034$ ), but no evidence for this association was observed in males ( $p = 0.96$ ), consistent with earlier reports<sup>15, 20</sup>. The methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria (*MMACHC*) locus (rs4660306) nominally associated with Hcy in the sex-combined meta-analysis ( $\beta = 0.053$ ,  $p = 0.043$ ); this effect was entirely driven by males ( $\beta = 0.14$ ,  $p = 6.0 \times 10^{-4}$ ) and absent in females ( $\beta = -0.0038$ ,  $p = 0.91$ ).

One variant, rs42648 near GTP binding protein 10 (*GTPBP10*), was nominally significant in the sex-combined meta-analysis ( $p = 0.019$ ) but had the opposite direction of effect as that



previously reported in a meta-analysis in European populations<sup>19</sup>. This variant differs in allele frequency between European and African populations (59% for European populations versus 39% for African populations for the G allele in 1000 Genomes) and has more variants in strong LD ( $r^2 > 0.8$ ) in European ( $n=21$ ) as opposed to African ( $n=4$ ) populations in 1000 Genomes project data; differing causal variants might explain this opposite direction of effect.

While the estimated direction of effect was the same, the well-studied non-synonymous polymorphism, rs1801133, in *MTHFR* at chromosome 1 did not reach significance ( $p=0.094$ ) in our analysis; this may be in part be due to the lower effect-allele frequency (14%) observed in these AA cohorts as opposed to European (33–47%)<sup>15, 16, 19</sup> and Filipino cohorts (22%)<sup>20</sup>.

## Discussion

To our knowledge, this study in 4,927 AAs from three community-based cohorts represents the largest GWAS for Hcy concentration in individuals of African descent yet conducted. We observed a significant heritable component for Hcy levels in JHS (estimated heritability 28%); this is somewhat lower than previous heritability estimates of 47%–70%, depending on the population<sup>8–11</sup>, but still supports the importance of assessing common variants for their contribution to Hcy levels. We observed genome-wide significant evidence for association at *NOX4*, a gene previously identified in a GWAS in EA females from the WGHS<sup>15</sup> and in a meta-analysis of EA males and females<sup>19</sup>. Previously identified variants near *NOX4*, *MTR*, *CBS*, and *MMACHC* were replicated in the sex-combined meta-analysis, with *CPS1* missense variant rs1047891 additionally replicated in females.

The most strongly associated SNP in the current study (rs2289125) is in *NOX4*; the *NOX4* locus has been previously associated with Hcy in two analyses in European-ancestry populations, including a meta-analysis of males and females<sup>19</sup> and an analysis of females only in the WGHS<sup>15</sup>. Associations between Hcy and *NOX4* have not been reported previously in an AA population. The NADPH oxidases are a family of enzymes that serve as a significant source of cellular reactive oxygen species (ROS), which play roles in both homeostasis and pathogenesis. Low to moderate levels of ROS contribute to important functions such as cell signaling, apoptosis, cell differentiation, fibrosis, and cellular migration; elevated levels of ROS are associated with cell-mediated inflammation and a variety of diseases including CVD<sup>42, 43</sup>. The *NOX4* gene is expressed in a wide array of tissue and cell types including cardiomyocytes, endothelial cells, and vascular smooth muscle cells<sup>43</sup>. *NOX4* expression may be upregulated by oxidized lipids, endoplasmic reticulum stress, injury to arterial walls, and ischemia, among other factors, with elevated expression reported in patients with atherosclerosis, hypertension, heart failure, stroke, and diabetes<sup>44</sup>. Upregulation of *NOX2* and *NOX4* may also contribute to Hcy-mediated apoptosis of endothelial cells<sup>45</sup>. Neither rs2289125 nor other variants in moderate LD ( $r^2 > 0.6$ ) in African populations are listed as significant expression quantitative trait loci (eQTLs) for *NOX4* or any other genes in any tissues tested in HaploReg v4.1<sup>46</sup>. However, rs2289125 is located in open chromatin in most tissues as tested by DNase hypersensitivity assays and does have evidence for protein binding in ENCODE ChIP-Seq experiments by

the transcription factors TATA-binding protein (TBP) and yin-yang-1 (YY1) and by TATA-box binding protein associated factor (TAF7), a subunit of the complex required for RNA polymerase II transcription. rs2289125 has also recently been found to associate with pulse pressure in European populations and increased NOX4 expression in endothelial cells<sup>47</sup>. In our analyses the signal at rs2289125 appeared distinct from the *NOX4* associations previously reported in Europeans for homocysteine, as it remained genome-wide significant when conditioning on either of the European *NOX4* variants (rs7130284 and rs11018628).

We also analyzed previously reported Hcy-associated variants in our AA meta-analysis to assess replication in this population (Table 3). Two of the listed variants, rs6940729 in *CD2AP* and rs28635199 near *CBS*, were identified in an African-ancestry population GWAS<sup>30</sup>. This *CBS* variant, as well as the lead *CBS* variants in two European population studies<sup>15, 19</sup>, replicated in our meta-analysis, but the novel variant in *CD2AP* reported by Kim et al. did not replicate here ( $p > 0.05$ ), although the direction of effect was concordant. In the sex-combined meta-analysis, we also observed evidence of association at *MTR* (rs2275565), which is a key enzyme for methionine biosynthesis. Nominal evidence of association was also observed at the less well-studied locus (*MMACHC*, rs4660306); this gene is associated with a disorder of vitamin B-12 metabolism characterized by accumulation of Hcy in serum<sup>48</sup>.

The well-known *MTHFR* 677 C>T polymorphism was not associated with Hcy in our meta-analysis. Similarly, this polymorphism was not associated with Hcy levels in a previous candidate gene analysis in CARDIA post-folic acid fortification<sup>31</sup> nor in an analysis from African ancestry participants in the WGHS<sup>32</sup>; our study had a greatly increased sample size compared with these studies, which each had < 1000 participants. We hypothesize that this variant's effect is greatly attenuated in our cohorts due to high folic acid consumption, as all tested Hcy levels after the introduction of widespread folic acid fortification of cereal grains (implemented in 1998)<sup>49</sup>. This is in contrast to the largest available European meta-analysis, which included cohorts with Hcy assessment both before and after this time period. The *MTHFR* polymorphism has been found in a previous comparison of European and Asian ancestry populations to have a lower effect size for both homocysteine and stroke risk in populations with higher average folate levels<sup>50</sup>. Greater reductions in stroke risk with folic acid supplementation interventional trials is observed in individuals with lower initial plasma folate levels<sup>25</sup>. Also, the minor allele frequency for this polymorphism is lower in our meta-analysis (14%) and in African populations in the 1000 Genomes project data (11%) than is generally reported in Europeans (35% in 1000 Genomes data), reducing power to detect effects of this *MTHFR* variant and making it likely a less important contributor to variation in Hcy levels in AAs as compared to European populations.

Sex-specific differences in circulating Hcy have been reported, but lower concentrations in females may be characteristic of the premenopausal years only<sup>6, 51</sup>. Higher levels in males may be partially explained by differences in muscle mass, as reflected by serum creatinine concentrations, and estrogen levels<sup>51</sup>. Reduced plasma Hcy concentrations in pregnant women and older women using estrogen supplementation supports the role of estrogen in these sex-specific differences in Hcy<sup>6, 51</sup>. Such differences may contribute to the sex-specific effects previously observed for genes involved in the regulation of Hcy metabolism;

based on this data, we conducted sex-stratified analyses. While no genome-wide significant variants were identified in analyses of males or females only, some evidence of sex-specific effects was observed for previously reported variants near *MMACHC* and in *CPS1*. The *MMACHC* variant was significant in males-only, with the observed sex-combined association driven entirely by male participants (in females the effect was non-significant and in the opposite direction). Sex-stratified results were not presented in the European meta-analysis by van Meurs et al.<sup>19</sup>, so it is unclear if this differential effect has been observed previously. As had been previously reported in European and Filipino populations<sup>15, 20</sup>, no evidence for the *CPS1* locus was observed in males, but the locus did replicate in females in our AA meta-analysis. Other variants at *CPS1* have been reported to impact coronary artery disease risk in females only<sup>52</sup>.

Strengths of this analysis include the largest population of African American subjects in a genetic analysis of Hcy<sup>30–32</sup>, though sample size is limited compared to European focused GWAS meta-analyses<sup>19</sup>. Sex-stratified analyses allowed assessment of sex-specific associations with Hcy; sex-stratified analyses are not available in previous genetic analyses in African Americans<sup>30–32</sup> or the largest European GWAS meta-analysis.<sup>19</sup> We also assessed the relevance of Hcy associations discovered in other ancestries to an African American population. Finally, all populations included in our analysis collected Hcy data post widespread folic acid fortification in the US, which is known to affect a population's blood folate and homocysteine levels and impact the effect size of the *MTHFR* polymorphism<sup>50</sup>. More than fifty countries have adopted folic acid fortification for commercially available foods such as wheat flour,<sup>49</sup> so this provides a more current view of the genetics of homocysteine. Limitations of our analysis include a lack of assessment of interactions with clinical factors other than sex relevant to homocysteine levels, such as menopause status, use of hormone replacement therapy, kidney function, and intake of folate and vitamins B6 and B12.<sup>6</sup> We also did not have data to perform Mendelian randomization analyses with Hcy associated SNPs for factors such as stroke and Alzheimer's disease in African Americans. Current data also suggests that modest elevations in Hcy are not causally related to coronary artery disease,<sup>19, 25</sup> limiting the relevance of our results to this outcome.

In conclusion, our findings provide additional insight regarding the genes that may be involved across and within populations in the regulation of Hcy levels. While the *NOX4* locus affects Hcy levels in both AAs and EAs, the lead variants are distinct, suggesting multiple signals at this locus in AAs. Other previously identified loci, including *MTR*, *CBS*, *MMACHC*, and *CPS1* in females, also impact Hcy levels in AA populations. The effects of a well-established *MTHFR* variant appear to be considerably smaller in AAs. Our findings further highlight the need to conduct GWAS in non-European populations and to assess potential sex-specific genetic association signals for biomarkers which differ significantly between males and females.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Analysis effort for this research was supported by the National Heart, Lung, and Blood Institute (NHLBI) R21 HL126045-02 (EML, LAL), R01 HL129132 (YL, APR), K99HL129045 (NCO), and T32 HL129982 (LMR).

The CARDIA Study is conducted and supported by the NHLBI in collaboration with the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging. MESA and the MESA SHARE project are conducted and supported by the NHLBI in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the NHLBI and the National Institute on Minority Health and Health Disparities. CARE genotyping for the three studies was performed at the Broad Institute of Harvard and MIT (Boston, MA, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0. Funding for CARE genotyping was provided by NHLBI Contract N01-HC-65226.

## References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation*. 2015; 131:e29–322. [PubMed: 25520374]
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med*. 1998; 338:1042–1050. [PubMed: 9535670]
3. Homocysteine Studies C. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. 2002; 288:2015–2022. [PubMed: 12387654]
4. Bertoia ML, Pai JK, Cooke JP, Joosten MM, Mittleman MA, Rimm EB, et al. Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease. *Atherosclerosis*. 2014; 235:94–101. [PubMed: 24819748]
5. Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. *Eur J Vasc Endovasc Surg*. 2009; 38:316–322. [PubMed: 19560951]
6. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. *Semin Thromb Hemost*. 2000; 26:263–279. [PubMed: 11011844]
7. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med*. 2002; 346:476–483. [PubMed: 11844848]
8. Siva A, De Lange M, Clayton D, Monteith S, Spector T, Brown MJ. The heritability of plasma homocysteine, and the influence of genetic variation in the homocysteine methylation pathway. *QJM*. 2007; 100:495–499. [PubMed: 17636160]
9. Nilsson SE, Read S, Berg S, Johansson B. Heritabilities for fifteen routine biochemical values: findings in 215 Swedish twin pairs 82 years of age or older. *Scand J Clin Lab Invest*. 2009; 69:562–569. [PubMed: 19343610]
10. Kullo IJ, Ding K, Boerwinkle E, Turner ST, Mosley TH Jr, Kardina SL, et al. Novel genomic loci influencing plasma homocysteine levels. *Stroke*. 2006; 37:1703–1709. [PubMed: 16741189]
11. Jee SH, Song KS, Shim WH, Kim HK, Suh I, Park JY, et al. Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography. *Hum Genet*. 2002; 111:128–135. [PubMed: 12189485]
12. Brustolin S, Giugliani R, Felix TM. Genetics of homocysteine metabolism and associated disorders. *Braz J Med Biol Res*. 2010; 43:1–7. [PubMed: 19967264]
13. Selhub J. Homocysteine metabolism. *Annual review of nutrition*. 1999; 19:217–246.
14. Collaboration HLT. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. *Am J Clin Nutr*. 2005; 82:806–812. [PubMed: 16210710]

15. Pare G, Chasman DI, Parker AN, Zee RR, Malarstig A, Seedorf U, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study. *Circ Cardiovasc Genet.* 2009; 2:142–150. [PubMed: 20031578]
16. Tanaka T, Scheet P, Giusti B, Bandinelli S, Piras MG, Usala G, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. *American journal of human genetics.* 2009; 84:477–482. [PubMed: 19303062]
17. Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, Jacques P, et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. *Human molecular genetics.* 2009; 18:4677–4687. [PubMed: 19744961]
18. Malarstig A, Buil A, Souto JC, Clarke R, Blanco-Vaca F, Fontcuberta J, et al. Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study. *Blood.* 2009; 114:1417–1422. [PubMed: 19525478]
19. van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. *Am J Clin Nutr.* 2013; 98:668–676. [PubMed: 23824729]
20. Lange LA, Croteau-Chonka DC, Marvelle AF, Qin L, Gaulton KJ, Kuzawa CW, et al. Genome-wide association study of homocysteine levels in Filipinos provides evidence for CPS1 in women and a stronger MTHFR effect in young adults. *Hum Mol Genet.* 2010; 19:2050–2058. [PubMed: 20154341]
21. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ.* 2002; 325:1202. [PubMed: 12446535]
22. Williams SR, Yang Q, Chen F, Liu X, Keene KL, Jacques P, et al. Genome-wide meta-analysis of homocysteine and methionine metabolism identifies five one carbon metabolism loci and a novel association of ALDH1L1 with ischemic stroke. *PLoS Genet.* 2014; 10:e1004214. [PubMed: 24651765]
23. Cotlarciuc I, Malik R, Holliday EG, Ahmadi KR, Pare G, Psaty BM, et al. Effect of genetic variants associated with plasma homocysteine levels on stroke risk. *Stroke.* 2014; 45:1920–1924. [PubMed: 24846872]
24. Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. *J Vasc Surg.* 2009; 49:711–718. [PubMed: 19157768]
25. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc.* 2016; 5
26. Beyer K, Lao JI, Carrato C, Rodriguez-Vila A, Latorre P, Mataro M, et al. Cystathionine beta synthase as a risk factor for Alzheimer disease. *Curr Alzheimer Res.* 2004; 1:127–133. [PubMed: 15975077]
27. Rai V. Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis. *Mol Neurobiol.* 2017; 54:1173–1186. [PubMed: 26820674]
28. Charles BA, Shriner D, Rotimi CN. Accounting for linkage disequilibrium in association analysis of diverse populations. *Genet Epidemiol.* 2014; 38:265–273. [PubMed: 24464495]
29. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. *Am J Hum Genet.* 2017; 100:635–649. [PubMed: 28366442]
30. Kim S, Nho K, Ramanan VK, Lai D, Foroud TM, Lane K, et al. Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. *J Alzheimers Dis.* 2015; 49:991–1003.
31. Tsai MY, Loria CM, Cao J, Kim Y, Siscovick DS, Schreiner PJ, et al. Polygenic association with total homocysteine in the post-folic acid fortification era: the CARDIA study. *Mol Genet Metab.* 2009; 98:181–186. [PubMed: 19577940]
32. Albert MA, Pare G, Morris A, Rose L, Buring J, Ridker PM, et al. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various

- race/ethnic groups: data from the Women's Genome Health Study. *Am Heart J.* 2009; 157:777–783. e771. [PubMed: 19332210]
33. Taylor HA Jr, Wilson JG, Jones DW, Sarpong DF, Srinivasan A, Garrison RJ, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. *Ethn Dis.* 2005; 15:S6-4–17.
  34. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. *Am J Epidemiol.* 2002; 156:871–881. [PubMed: 12397006]
  35. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation.* 2005; 111:1313–1320. [PubMed: 15769774]
  36. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. *J Clin Epidemiol.* 1988; 41:1105–1116. [PubMed: 3204420]
  37. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, et al. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. *Control Clin Trials.* 1991; 12:1S–77S. [PubMed: 1851696]
  38. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol.* 2010; 34:816–834. [PubMed: 21058334]
  39. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006; 38:904–909. [PubMed: 16862161]
  40. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, et al. Variance component model to account for sample structure in genome-wide association studies. *Nat Genet.* 2010; 42:348–354. [PubMed: 20208533]
  41. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]
  42. Lambeth JD, Kawahara T, Diebold B. Regulation of Nox and Duox enzymatic activity and expression. *Free radical biology & medicine.* 2007; 43:319–331. [PubMed: 17602947]
  43. Streeter J, Thiel W, Brieger K, Miller FJ Jr. Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. *Cardiovasc Ther.* 2013; 31:125–137. [PubMed: 22280098]
  44. Chen F, Haigh S, Barman S, Fulton DJ. From form to function: the role of Nox4 in the cardiovascular system. *Front Physiol.* 2012; 3:412. [PubMed: 23125837]
  45. Sipkens JA, Hahn N, van den Brand CS, Meischl C, Cillessen SA, Smith DE, et al. Homocysteine-induced apoptosis in endothelial cells coincides with nuclear NOX2 and peri-nuclear NOX4 activity. *Cell Biochem Biophys.* 2013; 67:341–352. [PubMed: 22038300]
  46. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* 2012; 40:D930–934. [PubMed: 22064851]
  47. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet.* 2017; 49:403–415. [PubMed: 28135244]
  48. Lerner-Ellis JP, Tirone JC, Pawelek PD, Dore C, Atkinson JL, Watkins D, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. *Nat Genet.* 2006; 38:93–100. [PubMed: 16311595]
  49. Crider KS, Bailey LB, Berry RJ. Folic acid food fortification-its history, effect, concerns, and future directions. *Nutrients.* 2011; 3:370–384. [PubMed: 22254102]
  50. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. *Lancet.* 2011; 378:584–594. [PubMed: 21803414]

51. Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. *Am J Epidemiol.* 2000; 152:140–148. [PubMed: 10909951]
52. Hartiala JA, Tang WH, Wang Z, Crow AL, Stewart AF, Roberts R, et al. Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. *Nat Commun.* 2016; 7:10558. [PubMed: 26822151]

Demographic characteristics of participants stratified by study. Studies include the Coronary Artery Risk Development in Young Adults (CARDIA) study, Jackson Heart Study (JHS), and the Multi-Ethnic Study of Atherosclerosis (MESA). SD, standard deviation, Q1, quartile 1, Q3, quartile 3.

**Table 1**

	CARDIA		JHS		MESA	
	Males	Females	Males	Females	Males	Females
N	116	222	1,134	1,827	738	890
Current Smoker, %	30	17	18	11	20	17
Age, years, mean $\pm$ SD	40 $\pm$ 3.7	40 $\pm$ 3.9	54 $\pm$ 13	55 $\pm$ 13	63 $\pm$ 10	62 $\pm$ 10
BMI, kg/m <sup>2</sup> , mean $\pm$ SD	29 $\pm$ 4.8	32 $\pm$ 7.6	30 $\pm$ 6.3	33 $\pm$ 7.8	29 $\pm$ 4.7	31 $\pm$ 6.5
Homocysteine, $\mu$ mol/L, , mean $\pm$ SD	10 $\pm$ 2.6	8.2 $\pm$ 2.1	10 $\pm$ 3.3	8.9 $\pm$ 4.0	11 $\pm$ 5.0	9.0 $\pm$ 3.2
Homocysteine, $\mu$ mol/L, , median (Q1, Q3)	9.4 (8.3, 11)	7.8 (6.8, 8.9)	9.5 (8.1, 11)	8.2 (6.9, 9.9)	9.7 (8.1, 12)	8.4 (7.1, 10)



Lead variants associated with homocysteine (Hcy) levels for sex-combined, males-only, and females-only meta-analysis across three cohorts. SE, standard error.

**Table 2**

Chr	SNP	Base Pair	Nearest Genes	Annotation	Effect Allele	Alternate Allele	Effect Allele Frequency	Both Males and Females		Males		Females	
								$\beta$ (SE)	P-value	$\beta$ (SE)	P-value	$\beta$ (SE)	P-value
11	rs2289125	89224453	NOX4	intronic	A	C	0.69	-0.15 (0.023)	$5.3 \times 10^{-11}$	-0.16 (0.037)	$1.3 \times 10^{-5}$	-0.15 (0.030)	$9.2 \times 10^{-7}$
8	rs144009661	20267580	LZTS1	intergenic	A	G	0.98	0.29 (0.076)	$1.3 \times 10^{-4}$	0.65 (0.12)	$6.3 \times 10^{-8}$	0.052 (0.098)	0.59
11	rs116810794	89352758	NOX4	intergenic	A	G	0.93	-0.24 (0.044)	$3.8 \times 10^{-8}$	-0.18 (0.071)	0.010	-0.28 (0.057)	$5.9 \times 10^{-7}$

Evidence of association for inverse normalized homocysteine (Hcy) levels at previously reported genome-wide association study loci. (F) indicates the prior association was reported in females only; (MF) indicates the association was reported in both males and females. Nominally significant associations ( $p < 0.050$ ) are highlighted in bold. AA, African American, Eur, European, Fil, Filipino, EAF, effect allele frequency, SE, standard error.

**Table 3**

Author	Chr	Nearest Gene	SNP	Original Study			Current Study								
				Effect Allele	EAF	Beta	Population	EAF	$\beta$ (SE)	P-value	$\beta$ (SE)	P-value	$\beta$ (SE)	P-value	
Lange, et al. (F)	1	<i>MTHFR</i>	rs1801133	A	0.22	0.083	Fil								
Tanaka, et al. (MF)	1	<i>MTHFR</i>	rs1801133	A	0.47	1.3	Eur								
van Meurs, et al. (MF)	1	<i>MTHFR</i>	rs1801133	A	0.34	0.16	Eur	0.14	0.052 (0.031)	0.094	0.039 (0.049)	0.42	0.061 (0.040)	0.13	
Pare, et al. (F)	1	<i>MTHFR</i>	rs1801133	A	0.33	0.048	Eur								
Hazra, et al. (MF)	1	<i>MTHFR</i>	rs12085006	A	0.43	0.04	Eur	0.32	0.0090 (0.023)	0.69	0.022 (0.035)	0.53	-0.0003 (0.030)	0.99	
van Meurs, et al. (MF)	1	<i>MMACHC</i>	rs4660306	T	0.33	0.044	Eur	0.19	0.053 (0.026)	<b>0.043</b>	0.14 (0.042)	<b><math>6.0 \times 10^{-4}</math></b>	-0.0038 (0.033)	0.91	
van Meurs, et al. (MF)	1	<i>MTR</i>	rs2275565	T	0.21	-0.054	Eur	0.46	-0.060 (0.020)	<b><math>2.7 \times 10^{-3}</math></b>	-0.043 (0.032)	0.18	-0.072 (0.026)	<b><math>5.7 \times 10^{-3}</math></b>	
Lange, L.A., et al. (F)	2	<i>CPS1</i>	rs7422339 (now rs1047891)	A	0.24	0.076	Fil								
Pare, G., et al. (F)	2	<i>CPS1</i>	rs7422339 (now rs1047891)	A	0.31	0.027	Eur	0.36	0.037 (0.022)	0.092	0.0018 (0.035)	0.96	0.059 (0.028)	<b>0.034</b>	
van Meurs, et al. (MF)	2	<i>CPS1</i>	rs7422339 (now rs1047891)	A	0.33	0.086	Eur								
van Meurs, et al. (MF)	6	<i>SLC17A3</i>	rs548987	C	0.13	0.060	Eur	0.39	0.037 (0.021)	0.078	0.056 (0.032)	0.081	0.023 (0.027)	0.40	
Kim, S., et al. (MF)	6	<i>CD2AP</i>	rs6940729	T	0.48	-0.027	AA	0.46	-0.0064 (0.021)	0.75	0.018 (0.033)	0.59	-0.022 (0.026)	0.40	
van Meurs, et al. (MF)	6	<i>MUT</i>	rs9369898	A	0.62	0.045	Eur	0.59	0.023 (0.021)	0.26	0.015 (0.032)	0.65	0.029 (0.027)	0.27	
Pare, G., et al. (F)	6	<i>MUT</i>	rs4267943	A	0.36	0.024	Eur	0.39	0.025 (0.021)	0.23	-0.0037 (0.033)	0.91	0.044 (0.027)	0.10	
van Meurs, et al. (MF)	7	<i>GTPBP10</i>	rs42648	A	0.40	-0.040	Eur	0.58	0.048 (0.021)	<b>0.019</b>	0.055 (0.032)	0.086	0.043 (0.027)	0.11	
Hazra, et al. (MF)	9	<i>GABBR2</i>	rs10986018	C	0.22	-0.06	Eur	0.12	-0.0085 (0.031)	0.79	-0.0058 (0.049)	0.91	-0.010 (0.040)	0.80	
van Meurs, et al. (MF)	10	<i>CUBN</i>	rs1801222	A	0.34	0.045	Eur	0.20	0.033 (0.025)	0.19	-0.0058 (0.040)	0.89	0.059 (0.033)	0.070	
van Meurs, et al. (MF)	11	<i>NOX4</i>	rs7130284	T	0.07	-0.12	Eur	0.14	-0.069 (0.030)	<b>0.023</b>	-0.045 (0.047)	0.34	-0.084 (0.039)	<b>0.030</b>	
Pare, G., et al. (F)	11	<i>NOX4</i>	rs11018628	G	0.07	-0.050	Eur	0.15	-0.14 (0.029)	<b><math>2.0 \times 10^{-6}</math></b>	-0.11 (0.045)	<b>0.014</b>	-0.15 (0.037)	<b><math>3.8 \times 10^{-5}</math></b>	
van Meurs, et al. (MF)	12	<i>HNF1A</i>	rs2251468	A	0.65	-0.051	Eur	0.89	-0.016 (0.032)	0.62	-0.065 (0.051)	0.20	0.017 (0.041)	0.68	
Pare, G., et al. (F)	16	<i>DPEP1</i>	rs1126464	C	0.24	-0.031	Eur	0.17	-0.035 (0.035)	0.32	-0.028 (0.055)	0.62	-0.039 (0.045)	0.38	
van Meurs, et al. (MF)	16	<i>DPEP1</i>	rs154657	A	0.47	0.096	Eur	0.11	-0.016 (0.033)	0.62	0.029 (0.052)	0.57	-0.046 (0.042)	0.27	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author	Chr	Nearest Gene	SNP	Effect Allele	EAF	Beta	Population	Current Study					
								Both Males and Females		Males		Females	
								$\beta$ (SE)	P-value	$\beta$ (SE)	P-value	$\beta$ (SE)	P-value
Kim, S, et al. (MF)	21	<i>CBS</i>	rs28635199	C	0.17	-0.030	AA	0.17	$2.6 \times 10^{-4}$	-0.13 (0.044)	$4.0 \times 10^{-3}$	-0.084 (0.036)	<b>0.018</b>
Pare, G, et al. (F)	21	<i>CBS</i>	rs6586282	A	0.18	-0.030	Eur	0.23	$6.1 \times 10^{-5}$	-0.097 (0.039)	<b>0.013</b>	-0.098 (0.031)	$1.7 \times 10^{-3}$
van Meurs, et al. (MF)	21	<i>CBS</i>	rs234709	T	0.45	-0.072	Eur	0.79	$6.5 \times 10^{-3}$	-0.050 (0.040)	0.21	-0.086 (0.034)	<b>0.012</b>